Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Creatine is reported by many to increase hair loss, though no scientific evidence supports this. Some use finasteride and minoxidil to manage hair loss, while others avoid creatine due to personal experiences.
RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.
An 18-year-old with hair thinning is using minoxidil and considering stopping creatine due to concerns about increased DHT and hair loss. Opinions on creatine's impact are mixed, and the user plans to stop it until they can access topical finasteride.
A user is concerned about hair loss from creatine and asks for precautions, mentioning treatments like Minoxidil, finasteride, and ketoconazole shampoo. Replies vary, with some users sharing personal experiences and others dismissing the concern.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
Finasteride users have mixed experiences with creatine; some experience increased hair loss, while others do not. Finasteride's DHT-blocking effects might counteract any DHT increase from creatine, but individual responses vary.
The user shared their experience with taking 30g of creatine daily, noting no hair loss and improved physical performance, but minimal mental performance benefits. They also use 1.25mg of finasteride every other day.
The conversation discusses the successful receipt of RU58841 powder in Canada, with no reported issues from a user in British Columbia. The original poster is curious about potential seizures by CBSA but hasn't purchased it yet.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
A change in the formulation of Dr. Reddy's Minoxidil, adding benzoic acid, has worsened scalp flaking and caused burning and bad smell. Users are considering switching to other brands or formulations, like Tugain by Cipla, to avoid these issues.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
An 18-year-old is considering using RU58841 for aggressive hair loss and is also thinking about taking creatine. Users suggest avoiding creatine due to its potential to increase DHT and recommend using topical finasteride instead.
The conversation is about finding a reasonably priced shampoo with piroctone olamine in the US. The user is cautious about trying new or smaller brands.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Creatine use with finasteride has mixed effects on hair, with some experiencing shedding and others noticing no impact. Many attribute concerns to individual sensitivity or unrelated factors.
Exploring a potential hair loss treatment using the enzyme AKR1C2 to locally reduce DHT levels. Challenges include enzyme delivery through the skin and high production costs, with gene therapy or stem cells suggested as future alternatives.
A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.
Finasteride and creatine are discussed for hair loss, with mixed opinions on creatine's impact. Some users report no hair loss with creatine, while others experience shedding, but finasteride is generally seen as effective.
A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.
The user has been using minoxidil and finasteride without success and is now trying a new product called Arata Mitoactive, which contains the ingredient y100. They plan to review its effectiveness themselves due to a lack of existing reviews.
Creatine use may lead to increased hair thinning, especially for those genetically prone to hair loss, prompting some users to stop its use. Topical finasteride is used to manage hair loss, but concerns remain about creatine's impact on hair density.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.
Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.